Scinai Immunotherapeutics (NASDAQ:SCNI) and Barinthus Biotherapeutics (NASDAQ:BRNS) Head-To-Head Analysis

Barinthus Biotherapeutics (NASDAQ:BRNS) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Barinthus Biotherapeutics and Scinai Immunotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1	0	2	0	2.33
Scinai Immunotherapeutics	1	0	0	0	1.00

Barinthus Biotherapeutics presently has a consensus target price of $4.00, indicating a potential upside of 468.02%. Given Barinthus Biotherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Scinai Immunotherapeutics.

Risk and Volatility

Barinthus Biotherapeutics has a beta of -0.67, suggesting that its stock price is 167% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.

Earnings & Valuation

This table compares Barinthus Biotherapeutics and Scinai Immunotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97 million	1.92	-$61.07 million	($1.88)	-0.37
Scinai Immunotherapeutics	$1.15 million	1.96	$4.80 million	($9.57)	-0.07

Scinai Immunotherapeutics has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Barinthus Biotherapeutics and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-70.13%	-56.09%
Scinai Immunotherapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 10.7% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Scinai Immunotherapeutics beats Barinthus Biotherapeutics on 8 of the 13 factors compared between the two stocks.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.